Japan Alteplase Clinical Trial (J-ACT) research results suggest that a low dose of tPA (0.6 mg/kg) intravenous thrombolytic therapy in the Japanese population can obtain similar clinical efficacy as the standard dose of National Institute of Neurological Disorders and Stroke (NINDS) and can reduce the risk of SICH (18). Here, PLAT is linked to Stroke.